Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-9-22
pubmed:abstractText
1. Six healthy subjects received cilazapril (2.5 mg once daily), propranolol (120 mg once daily), the combination of both and placebo for a period of 1 week each (wash-out phase 1 week). 2. Propranolol and cilazapril reduced systolic and diastolic blood pressure (BP) by 7 mm Hg at peak when compared with placebo. However after the combination, this reduction was more than doubled (18 mm Hg) and lasted longer. 3. There was a trend to lower and later peak concentrations for both drugs after administration of the combination. No clinically relevant pharmacokinetic interactions between cilazapril and propranolol were found. 4. The effects on blood pressure were confirmed in hypertensive patients (BP diastolic greater than 95 mm Hg). Thirteen patients were randomly allocated cilazapril (2.5 mg day-1) or propranolol (120 mg day-1] as part of a cross-over design. This was then followed by the combination. All treatment periods were of 3 weeks duration and all measurements were done 2 h after drug administration. 5. Cilazapril lowered the median sitting diastolic BP by 8 mm Hg, and propranolol by 9 mm Hg, whereas the combination reduced the diastolic BP by 19 mm Hg. 6. The results of these studies, attempting to elucidate drug-drug interactions, showed that combined use of propranolol and cilazapril resulted in a more pronounced and longer lasting blood pressure reduction, in healthy subjects and in patients with hypertension.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2434790, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2434792, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2436002, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2442547, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2580182, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2839668, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2849518, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2946925, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2959304, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-2974715, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-3034469, http://linkedlifedata.com/resource/pubmed/commentcorrection/2527545-7157921
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0306-5251
pubmed:author
pubmed:issnType
Print
pubmed:volume
27 Suppl 2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
317S-322S
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1989
pubmed:articleTitle
Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients.
pubmed:affiliation
Zentrum für Kardiovaskuläre Pharmackologie, Ze Ka Pha GmbH, Wiesbaden, Federal Republic of Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial